Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petrelintide in Obesity or Overweight
NCT06662539Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Hormonal Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of petrelintide in obesity (6 arms), sponsored by Zealand Pharma. Primary endpoint: Percent change from baseline in body weight at 28 weeks. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06662539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662539.